Second autologous transplantation for multiple myeloma patients relapsing after the first autograft - A pilot study for the evaluation of experimental maintenance therapies: Report of the prospective non-randomized pilot study of the Czech Myeloma Group

Onkologie

Volumn 27, Issue 3, 2004, Pages 275-279

  Krivanova A ^a   Hajek R ^a   Krejci M ^a   Scudla V ^b   Indrak K ^b   Bacovsky J ^b   Buchler T ^a   Svobodnik A ^c   Adam, Z ^a   Mayer, J ^a   Vorlicek J ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Maintenance therapy; Multiple myeloma; Retransplantation

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MELPHALAN; PAMIDRONIC ACID; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AUTOGRAFT; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EVALUATION; FEMALE; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MALE; MORTALITY; MULTIPLE MYELOMA; PATIENT; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PILOT STUDY; RELAPSE; SURVIVAL; TOXICITY; TREATMENT OUTCOME; CLINICAL TRIAL; CZECH REPUBLIC; DISEASE FREE SURVIVAL; FEASIBILITY STUDY; GRAFT REJECTION; METHODOLOGY; MIDDLE AGED; STATISTICS; STEM CELL TRANSPLANTATION; TREATMENT FAILURE; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CZECH REPUBLIC; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; GRAFT REJECTION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; STEM CELL TRANSPLANTATION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 3943073152     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077977     Document Type: Article

References (30)

1. Adam Z, Hájek R, Mayer J, Śčudla V, Vorlíček J: Multiple Myeloma and Other Monoclonal Gamapathies. Brno, Masaryk University Press, 1999, p 370.
2. Gregory WM, Richards MA, Malpas JS: Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials. J Clin Oncol 1992;10:334-342.
3. Harousseau JL, Attal M: The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Sem Hematol 1997;34:61-66.
4. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J, Tricot G: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;3:789-793.
5. Björsktrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Remes K, Marcus R, Barbui T, Alegre A, Majolino I, Carlson K, Boogaerts M, Coser P, Iriondo A, Sureda A, Lenhoff S, de Laurenzi A, Bladé J, Ferrant A, Goldstone AH, Gahrton G: Autologous stem cell transplantation in multiple myeloma - the 1999 EMBT registry update. Bone Marrow Transplantation 1999;23(Suppl 1):100(abstr. 435).
6. Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C, Montes A, Hickish T, Nicolson M, Johnson P, Treleaven J, Raymond J, Gore M: A randomized trial of maintenance interferon following highdose chemotherapy in multiple myeloma. Longterm follow up results. Br J Haematol 1998;102:495-502.
7. Dyson PG, Horvath N, Joshua D, Barrow L, Van Holst NG, Brown R, Gibson J, To LB: CD34+selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilization in multiple myeloma. Bone Marrow Transplant 2000;25:1175-1184.
8. Hajek R, Adam Z, Vasova I, Kral Z: Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation. Acta Med Austriaca 1996;23:85-91.
9. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R: A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-97.
10. Goldschmidt H, Hegenbert U, Wallmeier M, Hohaus S, Engenhart R, Wannenmacher M, Haas R: High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma. Ann Oncology 1997;8:243-246.
11. Attal M, Harousseau JL, Facon T, et al.: Double autologous transplantation improves survival of multiple myeloma patients. Final analysis of a prospective randomized study of the Intergroupe Francophone du Myelome IFM 94. Hematology J 2003;4(Suppl):58.
12. Hajek R, Vasova I, Adam Z, Mayer J: New approaches to management of multiple myeloma. Acta Med Austriaca 1996;23:91.98.
13. Hajek R, Adam Z, Krivanova A, Doubek M, Koristek Z, Vorlicek J: Current role of immunotherapy in multiple myeloma. Acta Med Austriaca 1998;3:79-86.
14. Adam Z, Krejčí M, Bačovský J, Hejlová N, Kuča B, Švojgrová M, Fraňková H, Gumulec J, Janča J, Vepřek K, Januška B, Lehanka F, Rezek Z, Praskač P, Cahová S, Vránová M, Papajík T, Králová E, Novotná J, Ščudla V, Koza V, Drbal J, Faber E, Mareschova I, Hajek R: Treatment of multiple myeloma with myeloablative chemotherapy followed with autologous transplantation and maintenance therapy with interferon or interferon and dexamethasone. Intern Med 1998;44:400-408.
15. Hajek R, Butch AW: Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma. Med Oncol 2000;17:2-15.
16. Anderson KC: Novel biologically based therapies for myeloma. Cancer J 2001;Suppl 1,:S19-S23.
17. Büchler T, Michálek J, Kovářová L, Musilová R, Hájek R: Dendritic cells in the treatment of hematological malignancies. Hematology 2003;8:97-104.
18. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571.
19. Barlogie B, Tricot G, Anaissie E: Thalidomide in the management of multiple myeloma. Semin Oncol 2001;28:577-582.
20. Schey S, Jones R, Raj K, et al.: A phase I study of an immunomodulatory thalidomide analogous (CC 4047) in relapse/refractory multiple myeloma. Exp Hematol 2002(Suppl 1);98:(abstr. 248).
21. Desikan R, Fassas A, Munshi N, Badros A, Zangari M, Toor A, Morris C, Barlogie B, Tricot G: Intensive consolidation therapy after tandem transplants further improves the outcome of multiple myeloma (MM) patients. Blood 2000;96(Suppl 1):168a (abstr. 730).
22. Hájek R, Zackova D, Penka M, et al.: Autologous transplantation in CML patients using interleukin 2 activated graft followed with IL-2 and GM-CSF immunotherapy. Bone Marrow Transplant 2000;25 (Suppl 1):100(abstr. 278).
23. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115-1123.
24. Zar JH: Biostatistical Analysis (ed2). London, Prentice Hall, 1984, p 686.
25. Křivanová A, Hájek R, Adam Z: "T2model"- A clinical experimental model for evaluation of the effect of the new experimental perspective approaches in multiple myeloma patients (the results of pilot study). Bone Marrow Transplant 2000;25 (Suppl 1):S223.
26. Ščaudla V, Bačovský J, Indrák K, Kodousková V, Vytřasová M, Faber E, Papajík T, Vavrdová V, Adam Z, Hájek R, et al.: The therapy results and improvement of prognosis of multiple myeloma in 40 years in Moravia - evaluation of 562 patients. Vnitř Lék 48 2002;8:707-717.
27. Sirohi B, Powles R, Singhal S, Treleaven J, Kulkarni S, Sankpal S, Goyal S, Horton C, Mehta J: Second high-dose melphalan autografts for myeloma patients relapsing after one autograft: Results equivalent to tandem transplantation. Bone Marrow Transplant 2002;29(Suppl 2):S12(abstr 121).
28. Sancetta R, Piccin A, Pomponi F, Raimondi R, Miggiano MC, et al.: Second autologous stem cell transplantation is an effective salvage therapy in relapsing or progressing multiple myeloma patients: A single centre experience. 42nd Ann Meeting Am Soc Hematol 2000;(abstr. 3445).
29. Anagnostopoulos A, Aleman A, Weber D, Andersson B, et al.: IL-2 activated autologous progenitor cell transplant, followed by post transplant treatment with IL-2 does not seem to increase responses in multiple myeloma pts.treated with thiotepa, busulfan and cyclophosphamide as a preparative regimen. 42nd Ann Meeting Am Soc Hematol 2000;(abstr. 3443).
30. Barlogie B, Spencer T, Tricot G, Zeldis J, Munshi N, Zangari M, Badros A, Toor A, Shaughnessy A: Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM). Blood 2000;96(Suppl 1):514a (abstr. 2213).